Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review

Crohn’s disease and ulcerative colitis are the two most common categories of inflammatory bowel disease (IBD), which are characterized by chronic inflammation of the intestine that comprises the patients’ life quality and requires sustained pharmacological and surgical treatments. Since their aetiol...

Full description

Saved in:
Bibliographic Details
Published in:Mediators of Inflammation 2015-01, Vol.2015 (2015), p.515-528-047
Main Authors: Algieri, Francesca, Rodriguez-Nogales, Alba, Rodriguez-Cabezas, M. Elena, Risco, Severiano, Ocete, M. Angeles, Galvez, Julio
Format: Article
Language:English
Subjects:
Aloe
Andrographis
Artemisia absinthium
Biomedical research
Boswellia
Cannabis
Care and treatment
Clinical trials
Curcuma
Cytokines
Drugs
Health aspects
Humans
Inflammation
Inflammatory bowel disease
Inflammatory bowel diseases
Inflammatory Bowel Diseases - drug therapy
Inflammatory Bowel Diseases - etiology
Irritable bowel syndrome
Materia medica, Vegetable
Medical research
Medicine, Experimental
Phytotherapy
Plant extracts
Plant Extracts - therapeutic use
Quality
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Crohn’s disease and ulcerative colitis are the two most common categories of inflammatory bowel disease (IBD), which are characterized by chronic inflammation of the intestine that comprises the patients’ life quality and requires sustained pharmacological and surgical treatments. Since their aetiology is not completely understood, nonfully efficient drugs have been developed and those that show effectiveness are not devoid of quite important adverse effects that impair their long-term use. Therefore, many patients try with some botanical drugs, which are safe and efficient after many years of use. However, it is necessary to properly evaluate these therapies to consider a new strategy for human IBD. In this report we have reviewed the main botanical drugs that have been assessed in clinical trials in human IBD and the mechanisms and the active compounds proposed for their beneficial effects.
ISSN:0962-9351
1466-1861
DOI:10.1155/2015/179616